A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab VersusPlacebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients WithHigh-risk, Estrogen Receptor-Positive (ER+), Human Epider
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
November 22, 2019
End Date
October 12, 2023
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
November 22, 2019
End Date
October 12, 2023